Why the study?
Androgen deprivation therapy may increase cardiovascular disease risk, and limited data suggest GnRH antagonists may carry a lower risk than GnRH agonists.
Does GnRH antagonist improve endothelial function or reduce cardiovascular events compared to GnRH agonist in men with advanced prostate cancer and preexisting cardiovascular disease?
Population
80 men with prostate cancer and preexisting cardiovascular disease
Comparison
GnRH agonists vs GnRH antagonists
Design
Phase II randomized open-label study
Follow-up
1 year
Authors
Loading...
GnRH antagonists showed no endothelial benefit over agonists; leaves open whether they reduce cardiovascular events in prostate cancer patients with preexisting CVD.
Does GnRH antagonist improve endothelial function or reduce cardiovascular events compared to GnRH agonist in men with advanced prostate cancer and preexisting cardiovascular disease?
In men with prostate cancer and preexisting cardiovascular disease, GnRH antagonists may significantly reduce the risk of major cardiovascular events compared to GnRH agonists, despite no observed difference in endothelial function.
Margel et al. (2019) studied this question.